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Response to the Council of Europe Human Rights Commissioner’s
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Franco D’Alberton f, Alex Springer g, Olaf Hiort h,*,
on behalf of the Management Committee of the European Cooperation in Science and
Technology Action BM1303y
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cCongenital Adrenal Hyperplasia Support Group, Cambridge, UK; dDSD Nederland Support Group, Amsterdam, The Netherlands; e School of Medicine,
University of Glasgow, Glasgow, UK; f Paediatric Endocrinology Unit, Department of Paediatrics, S. Orsola-Malpighi University Hospital of Bologna, Bologna,
Italy; gDepartment of Paediatric Surgery, Medical University of Vienna, Vienna, Austria; hDivision of Experimental Paediatric Endocrinology and Diabetes,
Department of Paediatrics and Adolescent Medicine, University of Lu¨beck, Lu¨beck, GermanyInMay 2015, the Council of Europe (COE), represented by its
Commissioner for Human Rights, published an issue paper
on human rights and intersex people.
While we appreciate that the paper aims to increase
public understanding of how children and adults live with
these conditions and are cared for, and is concerned with
the fundamental human rights related to this community,
we feel that it is flawed in the following respect. First, we
question the authority of the Lesbian, Gay, Bisexual, and
Trans (LGBT) movement to speak on behalf of this
community and their families. Second, we feel that views
from important stakeholders such as support and advocacy
groups and associated health care professionals are
underrepresented, and we do not think the ideas outlined
are those of the mainstream in the affected community.
Third, current medical practice is misunderstood. Fourth,
some of us think the term intersex people is not widely
recognised as appropriate among adults and children
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the community of people with variant sex development
We share the concerns of intersex activists regarding the
discomfort of society towards gender variances, but while
we recognize the powerful campaigning voice of LGBT
groups, we have serious concerns about their involvement
in representing people with variant sex development. No
such organisations have approached support or advocacy
groups about adding ‘‘I’’ to the acronym, as in the LGBTI that
is sometimes quoted, andwe have no record of LGBT groups
in Europe working together with clinical services in
optimising care, or of any parental support services having
been put in place by them. Grants allocated to LGBT groups
to manage ‘‘intersex issues’’ cannot be justified as good use
of taxpayer money without consulting such representative
stakeholders. Rather, we would argue that the adoption of
intersex issues by LGBT under the umbrella of human rights,
with the assumption that intersex is per se related to sexualiversity Hospital, Princess Elizabeth Kinderziekenhuis, De Pintelaan 185,
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detrimental effect on societal understanding of variances
in sex development and undermines the efforts of many
people working towards optimal outcomes.
2. Views from the affected community
Intersex activists have often been very effective campaign-
ers, but it is less clear whether they are embedded in and
fully represent the community of ordinary people living
with variant sex development and their families.
We think it is important to distinguish between the
activist voices driving the COE paper and the many
community groups who have, from the beginning, taken
a support and advocacy approach and have successfully
fulfilled a conciliatory role. Their views have greatly
influenced medical thinking about care and about how to
communicate the issues at stake, challenging both medical
and wider social understandings around sex and gender,
and questioning the decision-making processes and medi-
cal necessity of some forms of treatments and interventions.
While many of the concerns raised in the COE paper are
recognised and shared by such advocacy and support
groups, these groups offer a different perspective onwhat is
needed to address these concerns. Yet they are not given a
voice in the COE paper. Why is that?
3. Current medical practice
While the COE paper notes serious concerns about past
medical practice, some of which unfortunately persist, it
does not recognise what has changed nor what is now
widely understood as best practice in the field (Supple-
mentary content). Current medical practice aims to offer a
holistic approach and to bring various disciplines together,
including the voice of parents and families [1,2]. It (pro-
)actively engages with family and support groups to answer
their needs effectively, and puts major efforts in reconcep-
tualising care for individuals with variant sex development
to limit interventions, offering alternative perspectives at
the same time [3,4]. The ultimate goal of such an approach is
to optimise outcome while guaranteeing access to special-
ised health care when needed and building a trustful
relationship between affected individuals, their families,
and the medical professionals caring for them [5].
What the paper calls ‘‘current medical approaches’’ is to
a large extent inconsistent with recently published data and
current medical practice [6]. Health care experts and
advocates share frustration at the slow implementation
of principles agreed on in the 2006 consensus statement
and since. However, by not recognising the ongoing
evolution in medical thinking thoughtfully and in collabo-
ration with advocates and support groups and by over-
looking the positive changes that have beenmade regarding
disclosure [7], gender assignment [8], prenatal dexametha-
sone treatment [9], and approaches to vaginal hypoplasia
[10], the COE paper seems outdated and risks an impression
that sensationalises rather than illuminates these condi-
tions. Indeed, we are concerned about the impact onordinary families and people living with these conditions
who may read the paper and withdraw from (medical or
psychological) care and/or social interactions, and we urge
the COE to reflect on this.
4. The term intersex
We understand that some adults reject themedicalisation of
variant sex development and the word disorder. By the same
token, some of us would argue that the majority of medical
professionals, and many patients and parents, consider the
term intersex inappropriate and feel that it increases a sense
of stigma around individuals living with these conditions,
rather than addressing them. The terms differences of sex
development and variances of sex development are sometimes
used to refer to the conditions as a group, although inpractice
families and affected individuals tend to use the specific
name for their condition or that of their child, and fewwould
refer to themselves or their child as ‘‘intersex’’.
In conclusion, we argue that the COE paper misunder-
stands and thus may misrepresent both current standards
of care and the views of the affected community. We
urgently suggest that the COE strengthens the legitimacy of
the paper by consulting more widely with other stake-
holders, including recognised centres of expertise for
differences of sex development, overarching structures
such as the developing European Reference Network, and
established patient representative groups.
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